We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Vitamin C Could Prevent AF Following Cardiac Surgery

By HospiMedica International staff writers
Posted on 17 Feb 2017
Print article
Image: New research looks at how Vitamin C benefits cardiac surgery patients, and can reduce the risk of post-op AF (Photo courtesy of Natural News).
Image: New research looks at how Vitamin C benefits cardiac surgery patients, and can reduce the risk of post-op AF (Photo courtesy of Natural News).
A new study suggests that vitamin C may prevent post-operative atrial fibrillation (AF) in cardiac surgery patients and may also shorten the duration of their hospital stay.

Researchers at the University of Helsinki and Helsinki University Central Hospital conducted a meta-analysis of randomized studies from the Cochrane CENTRAL Register, MEDLINE, and Scopus databases for trials on vitamin C that measured AF as an outcome in high-risk patients. They identified 14 randomized trials totaling 2,006 patients who had undergone cardiac surgery, and one trial with 44 patients that had investigated the recurrence of AF after successful cardioversion.

Five cardiac surgery trials carried out in the United States uniformly found no effect of vitamin C against post-operative AF; in contrast, nine cardiac surgery trials conducted outside of the U.S. found a mean reduction of 44% in the incidence of post-operative AF, and there was no heterogeneity between these nine trials. Five of the latter trials were carried out in Iran, two in Greece, one in Slovenia, and one in Russia. The single study on the recurrence of AF after a successful cardioversion, which was carried out in Greece, found that vitamin C decreased the risk of AF recurrence by 87%.

The studies also found that oral administration of vitamin C decreased the occurrence of post-operative AF by 73%, whereas intravenous (IV) administration decreased it by 36%. In contrast, oral administration shortened the length of hospital stay by only 7% (0.4 days), whereas IV administration decreased it by 16% (1.5 days). Accordingly, vitamin C IV administration has a greater influence on the length of hospital stay, but less on the occurrence of post-operative AF. The study was published on February 1, 2017, in BMC Cardiovascular Disorders.

“Vitamin C is a safe low-cost essential nutrient. Given the consistent evidence from the less wealthy countries, vitamin C might be administered to cardiac surgery patients, although further studies are needed to find out optimal protocols for its administration,” concluded study authors Harri Hemilä, MD, PhD, of UH, and Timo Suonsyrjä, MSc, of HUS. “There seems to be no rationale for further study of unselected patients in wealthy countries, but the effects of vitamin C for patients who have a particularly low documented level of vitamin C might still be worthwhile.”

Vitamin C, also known as ascorbic acid, is an essential nutrient involved in the repair of tissue, naturally found in citrus fruit, tomatoes, and potatoes. It was discovered in 1912, isolated in 1928, and first made in 1933. Vitamin C is a cofactor in at least eight enzymatic reactions, including several collagen synthesis reactions that are especially important in wound-healing and in preventing capillary bleeding. Ascorbate also acts as an antioxidant, protecting against oxidative stress. It is on the World Health Organization (WHO) list of essential medicines.

Print article



view channel

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.